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2 
Abstract 28 
Transcriptional regulation by the Estrogen Receptor α (ER) has been investigated mainly in breast 29 
cancer cell lines but estrogens such as 17β-Estradiol (E2) exert numerous extra-reproductive effects, 30 
particularly in the liver where E2 exhibits both protective metabolic and deleterious thrombotic 31 
actions. To analyze the direct and early transcriptional effects of estrogens in the liver, we determined 32 
the E2-sensitive transcriptome and ER cistrome in mice following acute administration of E2 or 33 
placebo. These analyses revealed the early induction of genes involved in lipid metabolism, which fits 34 
with the crucial role of ER in the prevention of liver steatosis. Characterization of the chromatin state 35 
of ER binding sites (BSs) in mice expressing or not ER demonstrated that ER is not required per se 36 
for the establishment and/or maintenance of chromatin modifications at the majority of its BSs. This 37 
is presumably a consequence of a strong overlap between ER and Hepatocyte nuclear factor 4 α 38 
(Hnf4α) BSs. In contrast, 40% of the BSs of the pioneer factor Foxa2 were dependent upon ER 39 
expression, and ER expression also affected the distribution of nucleosomes harboring dimethylated 40 
H3K4 around Foxa2 BSs. We finally show that, in addition to a network of liver-specific transcription 41 
factors including Cebpα/β and Hnf4α, ER might be required for proper Foxa2 function in this tissue. 42 
 43 
 44 
 45 
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3 
Introduction 48 
Estrogen receptors (Esr1: ERα, termed ER throughout the manuscript; and Esr2: ERβ) are ligand-49 
dependent transcription factors that mediate the effects of estrogens such as 17-β estradiol (E2) (1,2). 50 
Estrogens control the development, differentiation and function of tissues involved in reproduction, 51 
but are also pleiotropic hormones controlling the metabolism and homeostasis of many other tissues. 52 
They can be harmful or beneficial according to the target tissue, with deleterious effects in the 53 
development of cancers of uterus and breast, but protective effects on the bones, arteries and 54 
metabolism since they reduce the incidence of osteoporosis, atheroma, and type 2 diabetes (3). 55 
The molecular actions of ER have been extensively studied in vitro in human cell lines, using 56 
mostly the prototypical breast cancer cell line, MCF-7. Over the last decade, genome-wide analyses 57 
obtained from such in vitro models have greatly challenged the historical view of proximal ER-58 
directed gene regulation (4-6) and it is now accepted that, in breast cancer cells, ER can dynamically 59 
engage between 15,000 and 30,000 binding sites (ER BSs) across the genome. Once tethered to 60 
chromatin at these sequences, ER regulates transcription of its target genes through the dynamic 61 
recruitment of multiple partners including cofactors of diverse families of proteins and components of 62 
the transcriptional machinery (7-10). Importantly, most of the ER BSs that have been determined so 63 
far are thought to be enhancers located away from the transcriptional start site (TSS) of annotated E2-64 
sensitive genes (11,12), although transcription of so-called enhancer RNAs (eRNAs) could occur at 65 
these places (13,14). The actions of pioneer TFs have also been demonstrated genome-wide as 66 
essential for the accuracy and frequency of ER binding. FOXA1 is one of the most studied of these 67 
proteins (6,11,15). It can bind to condensed chromatin to prepare it for the subsequent recruitment of 68 
other TFs, presumably by acting as a recruitment platform for histone modification and/or 69 
nucleosome remodelling complexes (16-18). 70 
Whether these mechanisms actually apply in vivo remains uncertain and requires careful attention. 71 
Genome-wide analysis of the ER cistrome in tissue explants from normal human mammary glands 72 
has demonstrated that ER binding events in these differentiated primary cells are much more 73 
restricted than those in cancer cell lines (19). In addition, although ERs and FOXA have been shown 74 
to cooperate in establishing the estrogen-dependent protection of the liver against hepatocellular 75 
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carcinoma (20,21), the nucleosome positions and chromatin structure around Foxa sites were also 76 
found to be independent of Foxa1 and Foxa2 expression in differentiated adult mouse liver (22). This 77 
leads one to wonder whether Foxa proteins do indeed exert a pioneering influence on ER activity and 78 
whether they use similar mechanisms in the liver as those in human mammary gland. 79 
As well as establishing these mechanistic aspects of ER function in vivo, studying the actions of 80 
E2 in the liver in vivo is also of utmost physiological interest since estrogens play important protective 81 
and deleterious roles. For example, E2 directly contributes to liver protection from the deleterious 82 
consequences of metabolic stresses such as a High Fat Diet (HFD) since it prevents HFD-induced 83 
liver steatosis through the activation of hepatocyte ER (23,24). On the other hand, exogenous 84 
estrogens administrated for oral contraception or hormone replacement therapy at menopause 85 
stimulate the production of angiotensinogen, sex hormone-binding globulin and circulating hepatic 86 
coagulation factors (25). These changes are greatly enhanced by the oral route due to hepatic first-87 
pass and appear to contribute, at least in part, to an increased risk of venous thrombosis and its life-88 
threatening complication, the pulmonary embolism (26). It is thus of major interest to describe and 89 
understand the mechanisms of action of estrogen in the liver, since this organ represents an important 90 
target for these hormones and can mediate both the desired (protection against liver steatosis) and 91 
deleterious (contribution to increased risk of venous thrombosis) actions of estrogens. However, so far 92 
the estrogen-sensitive liver transcriptome and the ER cistrome have been characterized only under 93 
chronic hormonal treatment (20,27-29). 94 
Given this, we aimed to decipher the early steps of the mechanisms engaged by ER at the 95 
chromatin level that control liver gene expression following acute administration of E2 in vivo. To 96 
differentiate between ER-dependent and ER-independent processes, and to understand chromatin 97 
events induced by an ER deficiency, we gathered data from wild-type or ER knock-out (ERKO) 98 
mouse livers. Here, we demonstrate that although the liver transcriptional response to E2 is fully 99 
dependent upon ER expression, an ER deficiency has no drastic consequences on enhancer chromatin 100 
signatures. However, we provide evidence that ER is required for Foxa2 binding at a subset of sites, 101 
and that a network of other TFs may protect Foxa2 sites from loss of chromatin functionality. 102 
 103 
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Materials and Methods 104 
Ethics statement 105 
All procedures involving experimental animals were performed in accordance with the principles 106 
and guidelines established by the “Institut National de la Santé et de la Recherche Médicale” 107 
(INSERM) and were approved by the local Animal Care and Use Committee. 108 
Mice 109 
ER-null mice (ERKO) from a C57BL/6 genetic background were generated as previously 110 
described (30) and were kindly provided by Prof P Chambon (Strasbourg, France). Female wild-type 111 
(ERWT) and ERKO mice littermates were obtained from the same parents. Mice were housed in 112 
groups of 5 per cage and kept in a temperature-controlled facility on an artificial 12h light-dark cycle. 113 
Genotyping was systematically performed on DNA prepared from tail biopsies using a mix of specific 114 
primers P4 (intron 1): 5’-GCTTTCCTGAAGACCTTTCATATGGTG-3’, P3 (antisense in intron 2): 115 
5’-GGCATTACCACTTCTCCTGGGAGTCT-3’, and mESR1ex2: 5’-116 
CAATCGACGCCAGAATGGCCGAG-3’. Mice were ovariectomized at 4 weeks of age and then 117 
treated by oral gavage with placebo (castor oil, 5% ethanol) or E2 (1 mg/kg) at 10 weeks of age. 118 
Following anesthesia by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), 119 
mice were sacrificed 1 or 4 hours after gavage. Blood was collected by retroorbital puncture and livers 120 
were used immediately or snap-frozen in liquid nitrogen and stored at -80°C. 121 
RNA preparation 122 
Ovariectomized ERWT or ERKO mice were treated or not with E2 for 4 hours. Following the 123 
extraction of livers and tissue homogenization using a Precellys tissue homogenizer (Bertin 124 
Technology), total RNAs were prepared using GenElute Mammalian Total RNA Miniprep Kit 125 
(Sigma-Aldrich). For Rt-qPCR experiments, 1 µg total RNA was reverse transcribed using a High 126 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and subjected to qPCR. 127 
Gene expression arrays 128 
We used the One-Color Quick Amp Labeling kit (Agilent) to synthesize and label cRNAs using 129 
200 µg RNA, according to the manufacturer’s instructions. 600 ng Cy3-labelled cRNA were 130 
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hybridized to a SurePrint G3 Mouse GE microarray (8X60K) at the GeT-TRIX Genopole facility 131 
(Toulouse, France). Slides were scanned immediately and data were analyzed with Feature Extraction 132 
Software 10.10.1.1 (Agilent) using the default parameters. All subsequent analyses were done under R 133 
(www.r-project.org) using packages of Bioconductor (www.bioconductor.org). We used the limma 134 
package for data normalization, selecting spots with a weight of one in at least three arrays from at 135 
least one experimental group, and carried out normalization using the quantile method. Experimental 136 
groups were compared by analysis of variances (t-test) and p-values were adjusted by the Benjamini 137 
and Hochberg (BH) method. Genes were considered as differentially expressed between two 138 
experimental conditions when their adjusted p-value was lower than 0.05 and their fold change greater 139 
than 1.5. The lists of all significantly regulated genes are given in Supplemental File 1. Functional 140 
annotations were performed under the web-platform webgestalt 141 
(http://bioinfo.vanderbilt.edu/webgestalt/) (31). Enrichments were calculated over the genome 142 
reference, using a BH-corrected p-value<0.0001 and considering only categories including at least 3 143 
genes. Comparative analysis with publicly-available datasets at the NCBI's Gene Expression Omnibus 144 
website (http://www.ncbi.nlm.nih.gov/geo/) (32) used the generated lists of genes from GSE57804 145 
(33), GSE13265 (27), GSE45346 (28), GSE36514 (29) and GSE23850 for human MCF-7 (34). 146 
MeDIP and hMeDIP assays 147 
Immunoprecipitation of methylated or hydroxymethylated cytosines (MeDIP or hMeDIP, 148 
respectively) were performed as described previously (35) on liver genomic DNA prepared using the 149 
DNeasy Blood Tissue Kit (Qiagen). We used 5 μg genomic DNA and 2 μg anti-5mC antibody or 15 150 
μg DNA and 5 μg anti 5-hmC antibody for MeDIP or hMeDIP, respectively. Immunoprecipitated 151 
DNA was purified via standard phenol-chloroform and ethanol precipitation procedures, and 152 
resuspended in 100 μl TE. Two μl of these samples were used for qPCR reactions. 153 
ChIP experiments 154 
Livers were extracted from animals 1 hour after oral administration of placebo or E2, then sliced 155 
into small pieces and disrupted in 5 ml PBS by pressure through a 21G syringe needle. Cells from one 156 
half of a liver were fixed in 10 ml PBS containing 1% formaldehyde for 10 min at room temperature. 157 
Cross-linking was then stopped by incubation with 0.125M glycine at room temperature. Cells were 158 
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washed twice with PBS and then lysed in 1 ml buffer [10 mM Tris-HCl (pH 8.0), 10 mM NaCl, 3 mM 159 
MgCl2, 0.5% Igepal] containing 1X protease inhibitors (Complete Inhibitors, Roche). Extraction of 160 
nuclei was then performed by applying 50 strokes of potter on the suspension in an ice-cold Dounce 161 
followed by further incubation for 5 min at 4°C. Nuclei suspensions were then centrifuged at 13,000 162 
rpm at 4°C. Following two washes in PBS, nuclei were lysed by incubation in 4 ml lysis buffer [10 163 
mM EDTA, 50 mM Tris-HCl (pH 8.0), 1% SDS, 0.5% Empigen BB (Sigma)] on ice for 10 min and 164 
sonification using a Branson 250 apparatus (3 pulses of 20 sec at 50% power, with at least 1 min on 165 
ice between each pulse). SDS was then neutralized by addition of 400 µl 10% Triton X-100 and 166 
chromatin was further sonicated by two additional 14 min sonications of the lysed nuclei in a 167 
BioRuptor apparatus (Diagenode) operating at high intensity with 30 sec on/off duty cycles. 168 
Chromatin was then cleared by a 10 min centrifugation at 10,000 x g and the supernatants were 169 
pooled for further use. ChIP experiments were performed using 300 µl of these chromatin 170 
preparations and 2 μg antibodies (Supplemental Table 1), as previously described (34,35). DNA was 171 
purified on NucleoSpin™ columns (Macherey-Nagel) using NTB buffer. Subsequent qPCR analysis 172 
used 2 μl of 5-fold diluted input material and 2 μl of ChIP samples. 173 
ChIP-seq 174 
All ChIP-seq were performed on livers from the same 5 individuals per genotype and treatment 175 
groups. We pooled DNA originating from 20 different ChIP experiments performed as described 176 
above, i.e. 4 ChIP experiments per mouse. Construction of libraries and sequencing using an Illumina 177 
HiSeq apparatus were conducted at the IGBMC sequencing facility (Strasbourg, France). Reads were 178 
aligned onto the indexed chromosomes of the mm9 genome using bowtie 0.12.7 (36) with parameters 179 
allowing at most two mismatches, and selected for unique mapping onto the genome. Sequencing 180 
statistics are given in Supplemental Table 2. Due to the small amounts of recovered DNA in the ER 181 
ChIP experiments performed on livers from placebo and E2-treated ovariectomized animals, we 182 
combined reads obtained in two runs of sequencing to reach a representative sequencing depth. 183 
Extracted reads were converted to .wig signal files using samtools 0.1.12a (37) and MACS 1.4.1 (38) 184 
with default parameters. To minimize the bias of diverging sequencing depths between different 185 
samples immunoprecipitated with the same antibody, the signal intensities of a given .wig were 186 
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normalized so as to be comparable to the .wig file with the highest sequencing depth. Peak callings 187 
were then performed as described in (35) with different p-values and peaks defined as being 188 
constituted of at least 4 adjacent signals within 65 bp above the threshold values. Peak callings for 189 
histone marks ChIP-seq were done with a stringent p-value= 1e
-12
. All repetitive sequences were 190 
eliminated from the identified genomic regions using lists obtained from the UCSC (blacklist; 191 
http://genome.ucsc.edu/cgi-bin). Bed files corresponding to the genomic coordinates of identified ER 192 
BSs and Foxa2 BSs are given in Supplemental File 2. Motif analysis was performed using the 193 
CentDist algoriths (http://biogpu.ddns.comp.nus.edu.sg/~chipseq/webseqtools2) and SeqPos tool on 194 
the cistrome web-platform (http://cistrome.org/ap/) (39), and illustrated within Wordles pictures 195 
(http://www.wordle.net/). For SeqPos analyses, we restricted the analyses to the top 5,000 sites when 196 
required, as defined by their maximum mean intensity in a 1 kb window centered on each region. 197 
When required Sequences were declared enriched with a p-value<0.05 and Z-score>2.5. All 198 
integrative analyses of the ChIP-seq data were performed using home-made scripts and algorithms 199 
from the cistrome web-platform. Analysis of publicly-available fastq ER ChIP-seq data at the GEO 200 
(32) or Array Express (http://www.ebi.ac.uk/arrayexpress/) (40) websites were performed under the 201 
same conditions. ER datasets analyzed were the GSE52351 (33), GSE36455 (41), E-MTAB-805 (20) 202 
and GSE25021 (42) for MCF-7 cells. Genomic regions identified by ChIP-chip assays (43) were 203 
extracted from the supplemental material of the manuscript and converted from mm5 to mm9 genome 204 
annotation. The .bed files corresponding to the cistromes of other transcription factors were all 205 
obtained from the cistrome finder system (http://cistrome.org/finder/; 44,45): Foxa1 (GSM427090; 206 
46), Cebpα (GSM548908; 47), Cebpβ (GSM427088; 46), Pparα (GSM864671; 48), Rxrα 207 
(GSM864674; 48), GR (common peaks from replicates GSM1122512 and GSM1122515; 49), Esrrα 208 
(GSM1067408; 50), NR1D1 (GSM647029; 51), NR1D2 (GSM840529; 52) , HDAC3 (common peaks 209 
from replicates GSM647022, GSM647023 and GSM647024; 51) , NCor1 (GSM647027; 51), CTCF 210 
(GSM722759; 53) excepting Hnf4α (GSE57807; 54) and NKx3-1 (common peaks from duplicate 211 
GSM878195 and GSM878196; 55) data, which were re-analyzed with our scripts.  212 
Real-time PCR (qPCR) and statistics 213 
9 
Sequences of all oligonucleotides used in this study are given in Supplemental Table 3 (RNAs) 214 
and Supplemental Table 4 (ChIPs). Oligonucleotides for RT-qPCR were designed using 215 
NCBI/Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). All other primers were 216 
designed using the Primer3 program (http://frodo.wi.mit.edu/primer3/) (56). All ChIP-qPCR 217 
experiments were carried out using a BioRad MyiQ apparatus with 1 μM oligonucleotide and a 218 
BioRad iQ SYBR Green supermix with 50 rounds of amplification followed by determination of 219 
melting curves. RT-qPCRs were performed on 96.96 Dynamic Arrays for the microfluidic BioMark 220 
system (Fluidigm Corporation) or using an ABI ViiA 7 apparatus. All statistical analyses of qPCR 221 
data were performed using GraphPad™ Prism software. Mann-Whitney non-parametric t-tests were 222 
used to determine significant variations from controls. Heatmaps of expression values and qPCR data 223 
were all generated using MeV (57). To normalize the data obtained from microarray experiments into 224 
a similar dynamic range, expression values shown within the heatmaps were normalized per mRNA 225 
as Normalized value= [(Value) – Mean(Row)]/[Standard deviation(Row)].  226 
Data deposition 227 
The microarray and ChIP-seq data generated in this study have been submitted to the NCBI Gene 228 
Expression Omnibus website (http://www.ncbi.nlm.nih.gov/geo/) (32) under accession No. 229 
GSE70350.  230 
 231 
Results 232 
Establishment of E2- and ER-dependent transcriptomes in liver 233 
Estrous cycle-dependent (58) or estrogen-sensitive transcriptomes in harvested livers (33) or in 234 
native animals treated by chronic administration of hormones (27,28) have already been documented. 235 
Here, we aimed to characterize the ER-dependent mechanisms of transcription regulation in the liver 236 
in vivo and to correlate these data with data on ER binding to chromatin at shorter times of treatment. 237 
Therefore, we chose to treat ovariectomized female ER+/+ (ERWT) and their ER-/- (ERKO) 238 
littermate mice through gavage with E2 or placebo (P) for 4 hours, in castor oil solution. These 239 
conditions were deliberately chosen in order to engage the hepatic first-pass which is likely to have a 240 
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role in E2-induced venous thrombosis (26), as opposed to transcutaneous hormone injections. Liver 241 
mRNAs from ERWT or ERKO mice treated or not with E2 in these experimental conditions were 242 
then isolated and microarray analysis was performed. Differentially expressed genes between two 243 
conditions were considered significant when their fold change in expression were >1.5 with an 244 
adjusted p-value of <0.05. The list of all significantly regulated genes is given within Supplemental 245 
File 1. Despite a relatively elevated inter-individual variation in gene expression levels (Fig. 1A), 246 
these analyses were able to identify 124 E2-regulated mRNAs in ERWT, which corresponded to 110 247 
unambiguously annotated unique genes (Fig. 1B). Importantly, in ERKO animals, the E2 treatment 248 
did not significantly affect the transcriptional regulation of any genes (Supplemental Fig. 1). This 249 
result confirms that ER is required for the response of all of the identified genes to an acute treatment 250 
with E2. Approximately 80 % of the identified genes in ERWT mice were up-regulated by E2 (Fig. 251 
1A) and were grouped into functional annotations relevant for lipid and alcohol metabolisms, growth 252 
factor signalling and other functional pathways specific of the liver (Table 1). Interestingly, although 253 
performed in different experimental settings, 48 (44%) of the identified E2-sensitive genes here were 254 
similar to those determined previously following 3 days of treatment with the ER agonist PPT 255 
{4,4’,4’’-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol} (28) (Supplemental Fig. 2). Our data also 256 
identified 194 mRNAs (129 genes) whose expressions were significantly different in ERKO 257 
compared to ERWT mice in the absence of E2 treatment (Fig. 1A and 1B). The ER coding gene Esr1 258 
was included in these 129 genes, thereby validating our analyses. These ER-dependent genes were 259 
identified as involved in cell growth/differentiation but also in lipid metabolic processes and 260 
mammary gland development (Table 1). Independent RT-qPCR experiments confirmed the observed 261 
changes in regulation for 91% of the 45 tested E2-regulated genes and 41.7% of the 12 tested ER-262 
dependent genes (Supplemental Fig. 3). As illustrated within the Venn diagram depicted in Fig. 1B, 263 
only 10 of the ER-dependent and E2- sensitive genes also exhibited an ER-dependent basal 264 
expression. This may indicate that the remaining 119 genes with an ER-dependent basal expression 265 
are regulated by E2 (or other endogenous estrogens/signals) under different conditions of time or diet 266 
than those used in our analyses. The differential expression of these 119 genes in livers from ERKO 267 
vs. ERWT mice could also be an indirect consequence of ER gene inactivation in liver, whereby 268 
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dysregulation of one or more of these genes may provoke the observed effects. However, only a small 269 
proportion of the ER-dependent genes found here are similar to those reported by another study 270 
performed in mice with liver-specific ablation of Esr1 expression (29). So it is possible that the 271 
changes in gene expression that we observed here between ERWT and ERKO livers are due to 272 
alterations of the function of (an)other tissue(s).  273 
Identification of ER binding sites in liver 274 
To determine whether ER is a direct transcriptional regulator of the E2- and/or ER-sensitive 275 
transcriptomes identified above, and to obtain mechanistic insights into these regulations, we next 276 
established the cistrome of ER in placebo and E2-treated livers. In particular, we aimed to determine 277 
whether ER is bound to chromatin in the absence of E2, as has been reported in cultured cancer cells 278 
(59-62). Indeed, ER cistromes have already been determined for mouse liver by ChIP-chip (43,58) or 279 
ChIP-seq methods in intact (20) or harvested liver cells (33), however these have not been carried out 280 
in the absence of E2. Hence, we conducted ChIP-seq experiments to establish the cistrome of ER in 281 
livers from ovariectomized E2- or placebo- (P) treated wild-type mice. We used chromatin prepared 282 
from livers of ovariectomized E2-treated ERKO individuals as a control. To reduce any cistrome 283 
variation due to individual animal specificities, we pooled and sequenced the DNA fragments purified 284 
from ChIP experiments performed on chromatin prepared from five different animals. Sequenced 285 
reads were aligned onto the genome and enriched regions were identified at different p-values (Fig. 286 
2A). To determine the appropriate threshold enabling a comparison between the different cistromes, 287 
we calculated their overlap with decreasing significance (Fig. 2B). As expected, the overlap between 288 
two sets of genomic regions paralleled the threshold stringency. For instance, at a p-value of 10
-15
, 80% 289 
of the 87 ER BSs identified in placebo-treated ERWT animals were common with the 948 identified 290 
in E2-treated ERWT mice. In all subsequent analyses, we used ER cistromes determined with a 10
-5
 291 
p-value threshold, which constituted the inflexion point for all overlapping ER BSs determined under 292 
the different conditions. At this threshold value, 3,857 ER BSs were identified in livers from E2-293 
treated ERWT animals, 857 under control conditions, and 54 in ERKO (Fig. 2C). Using a similar 294 
approach we also confirmed that the ER cistromes from the liver overlap poorly with those reported 295 
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for the aorta and uterus (Supplemental Fig. 4) (33,41). Interestingly, 476 ER BSs detected in 296 
placebo-treated ERWT mice were not identified in E2-treated samples. Surprisingly, 14 additional 297 
regions were declared as specific to ERKO livers (Fig. 2C). Heatmaps of ChIP-seq binding values 298 
(Fig. 2D) as well as mean binding values (Fig. 2E) confirmed the presence of an ERKO-specific 299 
signal at these genomic regions (sub-panel #2 in Fig. 2D), indicating that these 14 BSs were likely not 300 
generated by a peak-calling approximation. These graphs also confirmed the specific binding of ER in 301 
ERWT livers either treated with E2 or placebo on corresponding ER BSs. This demonstrates that the 302 
placebo-specific ER BSs are not indicative of a residual binding of ER on the strongest sites observed 303 
in E2-treated livers. Finally, we observed that ER binding to the 345 ER BSs identified in placebo and 304 
E2-treated livers from ERWT animals was enhanced in hormone-stimulated conditions (Fig. 2E).  305 
Examination of ERKO and placebo-specific ER BSs 306 
To validate the conclusions that could be made from our ChIP-seq data, we used qPCR to analyse 307 
ER binding to genomic regions presumed to either (i) bind ER in ERWT animals in both presence or 308 
absence of E2 (series #1); (ii) specifically recruit ER placebo-treated ERWT mice (series #3); or (iii) 309 
bind an ER-like protein in ERKO mice (series #2). We also took five randomly chosen sequences that 310 
did not recruit ER (#0 regions). The heatmaps in Fig. 3 summarize the results of these experiments 311 
(mean data and statistics are shown in Supplemental Fig. 5) which were performed on ChIP samples 312 
prepared from four mouse livers (numbers on the top of the panel) that differed from those processed 313 
for ChIP-seq to generate independent data. A fraction of the pool of DNA that was subjected to high-314 
throughput sequencing (HTS) served as a control. The promoter of the Rplp0 gene was used as a 315 
normalizing ER-negative region, and two genomic regions located at the vicinity of the E2-regulated 316 
Gdf15 gene were used as controls: one mobilized ER (Gdf15.3) and one did not (Gdf15.2). The results 317 
of these experiments confirmed the expected binding of ER to ER BSs from the #1 series of genomic 318 
regions, and not to those from the #0 series (Fig. 3A, left side of the panel). Moreover, these data 319 
showed an elevated level of variation concerning the binding of ER to the #2 and #3 regions detected 320 
in the different samples. For instance, in only two of the samples (one being the HTS sample), a 321 
protein recognized by the antibody used in these assays was specifically recruited (enrichment>2) to 322 
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four of the five tested #2 regions supposedly specific for ERKO livers. These observations led us to 323 
hypothesize that the antibodies targeting the C-terminal region of ER used for the ChIP-seq may 324 
purify a small number of non-specific genomic targets. High variations in enrichment levels were also 325 
evidenced between the five samples in the case of the ERWT placebo-specific ER BSs. Hence, we 326 
performed ChIP-qPCR assays with a specific antibody directed against the N-terminal region of ER 327 
on the same preparations of chromatin. As shown within the heatmap on the right side of the Fig. 3A 328 
(mean data and statistics are provided in Supplemental Fig. 5), whilst we were able to validate the 329 
binding of ER to the #1 series of genomic regions using this different antibody, this was not the case 330 
on the ERKO-specific ER BSs (#2 sites). These data indicated that the ER binding sites detected in 331 
ERKO mice may have represented a false-positive background of the ChIP-seq experiments, due 332 
either to the antibody or the pipeline used for processing the sequencing tags. Furthermore, as shown 333 
in Table 2, no specific motif related to an ER binding could be detected in ERKO sites, contrasting 334 
with the classical sequences found in the ER BSs identified in ERWT mice, such as FOX, HNF4, SP1 335 
and AP1/AP2 motifs (full motif analysis is provided within the Supplemental Fig. 6 and 336 
Supplemental File 3). ERKO sites were therefore excluded from the subsequent analyses described 337 
in this manuscript. Likewise, the results obtained from these ChIP-qPCR experiments performed with 338 
the N-terminal antibody did not validate any of the 5 tested ER BSs specific for placebo-treated 339 
ERWT livers (compare the results obtained for the #3 series of genomic regions on left and right sides 340 
of Fig. 3A). This indicated that either none of the ER BSs falling in this placebo-specific category 341 
constitute actual sites of ER binding or that these sites may be subjected to extreme inter-individual 342 
variation. Hence, we conducted ChIP-qPCR on 14 more genomic regions of this #3 category using 343 
liver chromatin prepared from additional animals (5 treated with placebo and 3 with E2). Results of 344 
these experiments, illustrated within Fig. 3B, showed that 2 of these 14 sites (#3.18 and #3.19) were 345 
not detected in these independent experiments using the anti C-terminal antibody and that 5 (#3.7, 346 
#3.11, #3.17, #3.20 and #3.21) of the remaining 12 ERBSs were enriched in the DNA fractions 347 
enriched with the anti-N-terminal antibody.  348 
In conclusion, as in human cancer cells, a mobilization of ER on chromatin can be detected in the 349 
absence of ligand in livers from ovariectomized mice. The existence of genuine placebo-only sites 350 
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was also confirmed in our ChIP-qPCR experiments. However, their number, as determined from our 351 
ChIP-seq data, may be biased or even overestimated i) because of the use of a C-terminal antibody 352 
that can generate false-positive regions with low-level of enrichments (such as the 54 ERKO sites); 353 
and/or ii) because the N-terminal epitope targeted by the antibody used in our confirmation ChIP-354 
qPCR experiments is not accessible for chromatin-bound ER in placebo conditions. 355 
ER BSs are “enriched” in the proximity of liver-specific genes 356 
Interestingly, in E2- and placebo-treated animals, 14.5% and 12.9% of the identified ER BSs 357 
respectively were found at a short distance (<3kb) from the promoters of annotated genes (Fig. 4A). 358 
When compared to the ER cistromes determined for human breast cancer cells, such an enrichment 359 
was clearly different from those identified for ER in the liver, uterus and, albeit to a lower extent, the 360 
aorta (Fig. 4B and Supplemental Fig. 7). Indeed, in E2-treated MCF-7 breast cancer cells, only 2 to 4% 361 
of the ER BSs identified were located in the vicinity of gene promoters (<3kb) (Fig. 4B). Note that an 362 
additional hour of treatment of mouse with E2 (2 hours in total) did not affect the distribution of ER 363 
BSs across the genome (data not shown). Importantly, GREAT (63) functional annotation of the ER 364 
cistrome in the liver also indicated that genes located proximal to and/or in relation to the identified 365 
ER BSs were clearly associated with liver-specific expression, function and diseases, such as lipid 366 
homeostasis and responses to insulin (Table 3). These data showed that the E2-mediated regulation of 367 
the rate of gene transcription in mouse liver may involve more proximal mechanisms than in human 368 
cancer cell lines, i.e. through binding of ER and its coregulators in the vicinity of the TSS. This 369 
hypothesis was confirmed by the observation that 28% of liver E2-regulated genes exhibited at least 370 
one ER BS within a 0-5kb window around their TSS, compared to 13% in MCF-7 cells (Fig. 4C). 371 
Interestingly, 75% of the genes characterized by an ER-dependent basal expression were located at 372 
distances >25kb from any ER BS (Fig. 4C). Again, this may reflect either an indirect effect of ER loss 373 
on the transcriptional rate of these particular genes, or their preferential long-range regulation. Finally, 374 
apart from a slight increase for genes within a 1-5 kb window, the strength of gene regulation by E2 375 
could not be correlated with the distance between their TSS and the ER BSs neither in mouse liver nor 376 
MCF-7 cell lines (Fig. 4D). 377 
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ER loss impacts the chromatin status of the promoters of its target genes 378 
A loss of ER binding at some genomic regions could be either the source or a consequence of 379 
drastic changes in chromatin structure at these sites, including post-translational modifications of 380 
histones and DNA modifications. The nucleosomes located in active regulatory elements like 381 
enhancers exhibit histone marks such as H3K4me1, H3K4me2 and H3K27ac (64-66), and their DNA 382 
is globally characterized by low levels of CpG methylation that is inversely correlated to their 383 
hydroxymethylation status (35,67,68). Thus, we performed ChIP-seq experiments that aimed to 384 
determine the genome-wide location of nucleosomes marked with the H3K27ac or H3K4me2 385 
modifications. As shown within Fig. 5A, the mean enrichment of these two marks around ER BSs (as 386 
defined by the sum of ER BSs detected in placebo- and E2-treated animals) exhibited biphasic curves 387 
around the center of the ER BSs, reflecting the existence of modified nucleosomes surrounding 388 
poised/activated genomic regions (69-72). Importantly, the relative enrichment of ER BSs in 389 
H3K4me2 and H3K27ac were relatively similar in ERWT and ERKO mice (Fig. 5B). Furthermore, 390 
less than 3% of the ERBSs were overlapping with either the 4,084 or 2,137 genomic regions losing 391 
their H3K4me2 or H3K27ac marks in ERKO livers (Supplementary Fig. 8). This suggested that the 392 
binding of ER to its sites is not required for the establishment and/or maintenance of these chromatin 393 
modifications. Note that the presence of the two chromatin marks H3K4me2/H3K27ac slightly but 394 
significantly decreased at the promoter regions of genes transcriptionally down-regulated in ERKO 395 
livers (Fig. 5C), and conversely increased in the promoters of up-regulated ones. Interestingly, 396 
variations in H3K4me2 and H3K27ac contents were more coordinated in the promoters of up-397 
regulated genes than in those of down-regulated genes (Fig. 5D). This indicates that the promoter 398 
regions of genes undergoing a “gain of function” in ERKO livers may be subjected to stronger 399 
chromatin remodelling than genes with a reduced transcriptional activity in ERKO.  400 
Hnf4α may protect ERBSs from losing their chromatin functional state in ERKO liver  401 
In order to examine the possibility that some variations of chromatin functionality could occur in a 402 
specific sub-population of ER BSs, we clustered the profiles of H3K4me2 and H3K27ac 403 
modifications around these genomic regions (heatmaps of ChIP-seq signals in Fig. 6A). With the 404 
exception of the ER BSs classified within clusters 7, 9 and possibly 4 (mean signals are shown in Fig. 405 
16 
6B), no variations in H3K4me2 signals were apparent in ERKO compared to ERWT mice. 406 
Interestingly, in these two/three cases the enrichment levels of ER BSs in H3K4me2 did not 407 
significantly differ but the shape of the curves shifted from biphasic to monophasic shapes (see 408 
enlarged view in the corresponding panels). A similar shift was also observed in the case of the cluster 409 
4, but to a slighter extent. This suggests that the ER BSs included within clusters 7, 9 and possibly 4 410 
were changing their functionality/poised state. However, we did not observe any variations in 411 
H3K27ac levels in these clusters (Supplemental Fig. 9), indicating that this loss in functionality may 412 
only affect the stability and/or the presence of an H3K4me2-marked nucleosome at the center of the 413 
ER BS. 414 
To validate these genome-wide observations and give further details on the exact loss of 415 
functionality of ER BSs in ERKO mice, we next evaluated the enrichment of ten ER BSs with 416 
H3K4me1, H3K4me2 and H3K27ac by ChIP-qPCRs using chromatin prepared from the same E2-417 
treated ERWT and ERKO animals as previously described. The results of these experiments (data and 418 
statistics in Supplemental Fig. 10) are illustrated as heatmaps of enrichment in Fig. 7A. These data 419 
indicate that the presence of mono- or di-methylated H3K4 around the 10 tested ER BSs was not 420 
drastically affected in ERKO livers when compared to ERWT ones. The same results were observed 421 
for their K27 acetylation status. However, interestingly, in ERKO mice a small but significant 422 
increase in both H3K4me1 and me2 content was observed at the #1.3 ER BS, and an increase in 423 
H3K4me2 was seen at the #3.1 ER BS. These small increases in H3 modifications may be in 424 
accordance with the fact that, on some ER BSs, the shift from biphasic to monophasic shapes of 425 
enrichment observed by ChIP-seq actually reflects a more stable central H3K4me2-marked 426 
nucleosome. Finally, we envisioned that increased amounts of 5-mC or a decreased presence of 5-427 
hmC on enhancer DNA may have accounted for the observed loss of functionality of ER BSs in 428 
ERKO mice. To test this hypothesis, we performed (hydroxy-) methylated DNA immunoprecipitation 429 
experiments (abbreviated to MeDIP and hMeDIP) and evaluated the enrichment of sites of interest of 430 
these two modified bases using qPCR. The results of these assays (Supplemental Fig. 10, 431 
summarized in Fig. 7B) indicated that the 10 tested enhancers were poorly enriched in 5-mC, and that 432 
the loss of ER had no general impact on these levels, apart from a slight but not significant increase in 433 
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the #1.2 ER BS in ERKO mice. In most cases, the amount of the active 5-hmC mark was also similar 434 
between ERWT and ERKO mice, except for a slight decrease in the #1.2 and an increase in the #1.3 435 
ER BSs that paralleled their levels of H3K4me2. It could therefore be proposed that the #1.3 enhancer 436 
is in fact a counter-example gaining some chromatin functionality. 437 
Interestingly, clusters 4, 8 and 9 include ER BSs located away from TSSs and could thus be 438 
defined as putative enhancers (Fig. 6A). However, we did not find evidence of any motif for a 439 
transcription factor specific to cluster 8 or 9 that could explain why changes in H3K4me2 enrichment 440 
occur in the latter and not the former (motif analysis provided within Supplemental File 4). We 441 
previously observed that ER BSs were highly enriched in HNF4 motifs (see Table2 and 442 
Supplemental Figure 6), another nuclear receptor, crucial for liver functions (73). This led us to 443 
determine whether its presence may protect ER BSs from losing their chromatin functionality in 444 
ERKO livers. As previously performed for ER, we determined Hnf4α cistrome with different p-values 445 
to allow comparison between the different conditions, using data from another study (54). As shown 446 
within Fig. 8A and illustrated within the heatmap in Fig. 8B, we found that up to almost 77% of ER 447 
BSs were actually overlapping with Hnf4 α BSs. Importantly, when this overlap was lower for ER 448 
BSs belonging to clusters 7 and 9 (Fig. 8C), which are changing their functionality/poised state in 449 
ERKO livers. Therefore, this tie in with our hypothesis of a protective role of Hnf4 α against the loss 450 
of H3K4me2 mark on lost ER BSs.  451 
In summary, together these observations indicate that a loss of ER in the liver does not strongly 452 
impact the chromatin status of its BSs: only those with a reduced overlap with Hnf4α binding seem to 453 
present a less stable H3K4me2-marked nucleosome at their center. 454 
A proportion of the mouse liver Foxa2 cistrome is ER-dependent 455 
Our genomic data are in favor of ER acting on chromatin regions whose activation is independent 456 
of ER-binding. This could reflect the possible actions of an ortholog of a pioneering factor such as 457 
human FOXA1 (15,19). Foxa proteins are expressed in mouse liver, including the related Foxa1 and 458 
Foxa2 (74,75), and these proteins have been found to serve as a scaffold for ER to regulate gene 459 
transcription in the liver and prevent hepatocarcinogenesis (20,21). Hnf4α binding in mouse liver is 460 
also conditioned (at least on part of its sites) during development by Foxa2 (76,77). We therefore 461 
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sought to investigate the role of these proteins in the creation of an ER cistrome and mapped their 462 
binding sites by ChIP-seq using liver chromatin preparations from the same animals as those used for 463 
the ER ChIP-seq experiments. We first observed that the Foxa1 and Foxa2 cistromes were very 464 
similar, due to a cross-reaction of Foxa1 antibodies against the Foxa2 protein (data not shown). The 465 
Foxa1 cistrome was therefore not analyzed in the subsequent step. As previously, we determined the 466 
Foxa2 cistromes with different p-values. Whatever the significance level used, we observed that the 467 
Foxa2 cistrome was reduced in ERKO mice compared to ERWT mice (Fig. 9A), with 5,991 Foxa2 468 
BSs determined at a 10
-4
 p-value for ERKO compared to 11,767 for ERWT mice. As depicted within 469 
Fig. 9B, depending upon the p-value, 12 to 30% of ER BSs were found to recruit Foxa2, 470 
corresponding to 6-12% of the entire Foxa2 cistrome. Up to almost 90% of the Foxa2 sites identified 471 
in ERKO mice were also determined as Foxa2-positive in wild-type animals. At a fixed p-value of 10
-
472 
4
, we identified 7,746 lost Foxa2 BSs (Fig. 9C). Importantly, only a sixth of these lost sites 473 
(688+491=1,179) were ER-positive (Fig. 9C). These data indicate that the loss of Foxa2 binding 474 
could be, at least in part, an indirect effect of ER depletion. The Foxa2 ChIP-seq signal was 475 
apparently lower in ERKO mice than in ERWT mice at conserved sites (see heatmap in Fig. 9D and 476 
mean values in Fig. 9E), indicating that Foxa2 binding events might also be less frequent in livers not 477 
expressing ER. However, although independent ChIP-qPCR experiments mostly recapitulated the 478 
expected results on gained and lost Foxa2 sites (Supplemental Fig. 11, Fig. 9F), a significantly 479 
reduced mobilization of this factor was observed for only 1 (#4.7) out of 10 tested conserved Foxa2 480 
BSs (Fig. 9F). We hypothesize that the highly heterogeneous enrichments obtained for the different 481 
samples may have hindered the detection of possible differences. Importantly, although our 482 
microarray data indicated that Foxa2 mRNA expression was 10% lower in ERKO livers, this 483 
regulation was neither systematic nor significant as assessed by independent RT-qPCR and Western 484 
blot experiments (Supplemental Fig. 3 and Supplemental Fig. 12). 485 
Variations in the H3K4me2 content of nucleosomes included in lost Foxa2 BSs  486 
To better comprehend the possible events occurring at Foxa2 BSs in ERKO vs. ERWT livers, we 487 
used our ERWT and ERKO H3K27ac and H3K4me2 ChIP-seq data to determine the relative genome-488 
wide enrichment of Foxa2 BSs in these chromatin modifications that indicate active/poised enhancers. 489 
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As described previously for lost ER BSs, changes were observed only at Foxa2 BSs located within 490 
putative enhancers (data not shown). We therefore focused our analysis on BSs situated >5 kb from 491 
any annotated gene promoter and aligned the mean H3K4me2 and H3K27ac ChIP-seq signals to these 492 
sites (Fig. 10A). Data obtained indicate that there was a loss of the biphasic shape of enrichment in 493 
H3K4me2 in ERKO compared to ERWT mice at these lost Foxa2 BSs (seen enlarged view in Fig. 494 
10A). In contrast, both the shape and level of enrichment of these sites in H3K27ac were unaffected 495 
(Fig. 10A). To evaluate a possible direct link between ER expression and these changes in chromatin 496 
modifications at Foxa2 BSs, we subdivided lost Foxa2 BSs into those which concomitantly recruited 497 
ER or those which did not (Fig. 10B). In contrast to their unchanged H3K27ac levels, we observed 498 
that the enrichment of both categories of sites in H3K4me2 was lower in ERKO livers compared to 499 
ERWT. Importantly, this was also associated with the disappearance of the biphasic shape of 500 
H3K4me2 enrichment (Fig. 10B), a biphasic-to-monophasic change that was observed neither at 501 
conserved Foxa2 BSs nor at novel ones (Fig. 10A). This demonstrated that the observed changes were 502 
not generated due to a bias of the normalization of the ChIP-seq signals but rather reflected a 503 
significant change in the enrichment of nucleosomes surrounding or centered on lost Foxa2 BSs in 504 
H3K4me2. Furthermore, such a change in shape was not observed at the BSs determined in mouse 505 
liver for other transcription factors such as Ctcf, Pparα, Rxrα, GR and Esrrα (not shown). 506 
Independent ChIP-qPCR experiments (data and statistics provided in Supplemental Fig. 10) 507 
following the enrichment of some Foxa2 BSs in H3K4me1 and H3K4me2 mostly recapitulated the 508 
conclusions obtained from genome-wide studies, i.e. that there is a reduction in the amount of 509 
methylated H3K4 in nucleosomes surrounding lost Foxa2 BSs in livers from ERKO mice (Fig. 10C). 510 
These effects were small, which may reflect the slight reduction observed in the amplitude of the 511 
mean profiles of the whole-genome data. Furthermore, due to the limited resolution of ChIP-qPCR 512 
experiments, the transition from a biphasic to monophasic distribution over a 1.5-2 kb window may 513 
have little or even no impact on the qPCR-mediated amplification of a DNA fragment located within 514 
a Foxa2 BS. Interestingly, we also observed a reduction in the acetylation of H3K27 on four of these 515 
sites, which was not expected from the whole-genome ChIP-seq data. MeDIP evaluation of the 5-mC 516 
amounts present within lost Foxa2 BSs also showed no variations between ERWT and ERKO livers 517 
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(Supplemental Fig. 10; Fig. 10D). Altogether, these data indicate that the Foxa2-positive enhancers 518 
which were lost in ERKO livers did not undergo complete chromatin closure. This conclusion is 519 
reinforced by the fact that only two of the 15 tested Foxa2 BSs (#4.6 and #1.2) had reduced amounts 520 
of 5-hmC in ERKO livers (Fig. 10D). 521 
Liver-specific transcription factor networks may secure FoxA2 cistrome 522 
In order to gain further insights into the mechanisms responsible for the loss of Foxa2 BSs in 523 
ERKO liver, we next examined whether particular transcription factors could either protect the 524 
conserved Foxa2 BSs from loss, or be responsible for the loss. Reassuringly, the most enriched motifs 525 
in each group were those recognized by Foxa2 and other members of the Forkhead family of TFs 526 
(Table 4, example Wordle picture is given in Figure 11A for lost FoxA2 BSs; full analysis is 527 
provided within Supplemental File 3). Besides Forkhead motifs, the sequences of the three Foxa2 528 
BSs’ category included similar sets of motifs for TF binding. The most frequently identified 529 
sequences were those recruiting CEBP, HNF4α and other NRs such as RXR, RAR, NR1D1/D2, or the 530 
tumor suppressor NKX3-1. Importantly, CEBPA/B and HNF4α are known “liver-enriched” 531 
transcription factors (78-80). When examined more precisely, 38 or 68 motifs were specifically 532 
identified within lost or conserved Foxa2BSs respectively (Supplemental Fig.13). However, the 533 
different sets of TFs binding to these specific motifs do not create networks that can be associated 534 
with specific functions, as evaluated by their annotations through STRING (81; see Supplemental 535 
Fig.13) Furthermore, the expression levels of the transcription factors associated with these DNA 536 
sequences were not significantly affected by the inactivation of the Esr1 gene (Supplemental Fig. 13).  537 
Finally, we compared our different categories of Foxa2 BSs to the available cistromes of other TF 538 
determined by others in mouse livers. Those included Cebpα and Cebpβ, Hnf4α, other nuclear 539 
receptors, repressive co-regulators (Hdac and Ncor1) and Ctcf. We also included Nkx3-1 in our 540 
analyses since its motif was the most enriched in all Foxa2 BSs categories following FKH motifs. 541 
Furthermore, NKX3-1 was demonstrated to act as an inhibitor of ER activity in human cancer cells 542 
(82). Note however that the only available cistrome of this factor in mouse was determined in prostate. 543 
We also integrated a Foxa1 cistrome, although it may not be totally specific and include FoxA2 BSs. 544 
Strikingly, we observed that the overlaps of the conserved Foxa2 BSs with the cistromes of Foxa1, 545 
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ER, Hnf4α, Nkx3-1, Cebpα, Cebpβ and Rxrα were significantly higher as compared to what was 546 
observed for lost or gained Foxa2 BSs (Fig. 11B). This indicates that the binding of (at least) one of 547 
these other TFs -excluding ER of course- to genomic regions may help to preserve Foxa2 binding at 548 
these sequences. Interestingly, Hnf4α, Cebpα and Cebpβ were also found to be more often recruited 549 
on sites conserving their H3K4me2 or H3K27ac levels rather than on genomic regions with reduced 550 
or gained enrichment in these chromatin marks in ERKO livers (Supplemental Fig. 14). This 551 
suggests that this combination of factors may generally prevent changes of chromatin functionality to 552 
occur on the sites they engage in ERKO livers. 553 
 554 
Discussion 555 
The objectives of this study were dual: i) to identify mechanisms of actions of hepatic ER in vivo 556 
and in particular to test whether it can exert some influence in the absence of its ligand, and ii) to 557 
characterize short-term changes in liver response to estrogens following acute E2 administration that 558 
could explain how E2 could have opposite influences in liver.  559 
Indeed, a number of studies have demonstrated in rodents that E2 has protective roles against 560 
metabolic abnormalities: ovariectomy, whole body ER knock-out (ERKO) and aromatase KO, are all 561 
associated with increased body weight, impaired glucose tolerance, insulin resistance (IR) and liver 562 
steatosis (23,24,83). In contrast, the administration of estrogens by the oral route prescribed for 563 
contraception or for hormonal replacement therapy at menopause is associated with an increased risk 564 
of venous thrombosis and pulmonary embolism, presumably due to the impact of E2 on liver 565 
coagulation factor expression or activity. Here, we characterized in mouse liver sets of E2- and ER-566 
dependent genes which were associated with lipogenesis, but none with coagulation. Accordingly, the 567 
genes predicted to be controlled by enhancer regions losing or gaining the active chromatin marks 568 
H3K4me2 and H3K27ac in ERKO livers were associated with liver-specific functions (Supplemental 569 
Fig. 8). These observations tied in with the crucial role of ER in E2-mediated prevention of liver 570 
steatosis in mice fed with high fat diet. They also highlight species differences in the regulation of 571 
coagulation factors by E2 between human and mouse (84). We observed that 48 of the 110 E2-572 
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regulated genes identified here were also regulated following chronic estrogen treatment for three 573 
days (36). This number drastically decreased to only two common genes after a two week treatment 574 
(37) or even one when comparing our list with a dataset generated from isolated liver cells (33). This 575 
latter observation could be explained by the adaptation of the liver cell transcriptome following cell 576 
culture, a transcriptome that also depends on the culture conditions (85,86). These differences 577 
between the estrogen-sensitive transcriptomes following chronic or acute treatment of hormones 578 
indicate that each mode of administration or time of treatment has a differential physiological impact. 579 
Using conditions of short-term E2 administration and freshly-dissected liver, we detected ER 580 
binding to less than 4,000 genomic regions by ChIP-seq. This contrasts with the much larger ER 581 
cistromes determined in cultured human mammary cell lines such as MCF-7 cells (11,12). 582 
Interestingly, although we used chromatin prepared from livers treated for different times, our data are 583 
in agreement with some other studies that have also found limited ER cistromes in liver (43,58). 584 
Furthermore, it is tempting to speculate that this limited number of ER BSs could be the cause of the 585 
lower number of E2-regulated genes identified here in liver as compared to classical in vitro model 586 
such as cultured MCF-7 cells (up to 1,500 regulated genes; see 34 and ref 87). A large set of ER BSs 587 
was also determined in isolated mouse liver cells (33), which presented 3-fold more E2-sensitive 588 
genes than determined here following acute E2 treatment of liver. Importantly, although ~2-fold less 589 
numerous, 60% of the E2-bound ER BSs determined here were in common with those determined in 590 
(33). As discussed above, the discrepancy in the number of ER BSs could also be a direct 591 
consequence of the conditions of E2-treatment or liver cell differentiation. These conditions might, for 592 
instance, influence the expression of chaperone proteins such as p23, whose over-expression in MCF-593 
7 breast cancer cells is reported to enhance the number of ER BSs (88). However, we determined that 594 
72% of the 5,526 ER BSs identified by our pipeline using a ChIP-seq dataset generated from the liver 595 
of non-ovariectomized females (20) were in common with the different ER cistromes determined in 596 
E2-treated livers from ovariectomized females (Supplemental Fig. 4). This suggests that the ER 597 
cistrome may present some robustness in liver, contrasting with an intrinsically more versatile hepatic 598 
transcriptome generated by (i) a cellular heterogeneity; and (ii) a high number of individual-specific 599 
regulatory influences (metabolic/detoxification…). Importantly, as is the case for all other reported 600 
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ER cistromes in liver, a significant fraction of the ER BSs identified here were found to be located in 601 
relatively close proximity to E2 regulated genes (7 to 12%), compared to MCF-7 data (2%). A general 602 
consequence of the organization of the genome within the nucleus is the existence of chromatin loops 603 
(89) that link distant regulatory elements such as ER BSs to their target genes (90) within large (1 Mb) 604 
topologically associating chromatin domains (TADs) (91). Although long-range interactions between 605 
enhancers and gene promoters do of course exist in mouse liver (92,93), our data point to the 606 
hypothesis that their multiplicity and possible functional redundancy (34,94) might be curtailed in 607 
vivo for E2-transcriptional responses within this tissue. This could also be true in the uterus, in which 608 
almost 16% of the ER BSs were located <3 kb from gene TSSs (Supplemental Fig. 7) (41). 609 
Additionally, enhanced stability of the loops between enhancers and TSSs may also increase the 610 
number of detected binding events at promoters, which would have to be considered as phantom 611 
imprints of this stable chromatin organization. However, the observed enrichment of these proximal 612 
ER BSs in motifs that are able to directly recruit ER (EREs, AP1 or Sp1) partly excludes this 613 
hypothesis.  614 
We have also determined that ER could be detected at approximately 850 ER BSs in untreated 615 
livers from ovariectomized female mice, 40% of them also being engaged by ER in the presence of 616 
E2. However, the existence and functionality of the remaining 476 placebo-specific ER BSs remains 617 
unclear. These placebo-specific sites were not found enriched at the proximity of genes whose 618 
expression was repressed by E2, and less than 2% of them were located closer than 10 kb from the 619 
TSS of any annotated gene (data not shown). Furthermore, independent ChIP assays performed with 620 
an antibody directed against the N-terminal region of ER were able to confirm an ER commitment at 621 
only 5 of the 19 randomly chosen regions falling into the placebo-specific condition. This could 622 
reflect a problem of specificity of the antibody directed against the C-terminal region of the protein, 623 
since it was able to purify 40 genomic regions supposedly binding to ER in ERKO livers. 624 
Alternatively, the epitopes targeted by the anti N-terminal antibody may be less accessible than those 625 
recognized by the C-terminal antibody, although the recent structure of a DNA-bound ER complexed 626 
with cofactors would suggest the opposite (95). Finally, we can also postulate that the placebo-627 
specific ER BSs may specifically recruit the ERα 46 or ERα 36 isoforms of ER which are devoid of 628 
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its N-terminal region and are known to be expressed in mouse liver (96-98). Investigating this 629 
hypothesis will require the whole-genome cartography of the binding events of these isoforms to be 630 
established using specific antibodies combined with the generation of corresponding mouse models 631 
expressing only one of the three ER isoforms. 632 
Comparing the transcriptomes and the distribution of H3K4me2 and H3K27ac chromatin marks 633 
within the genome of ERWT and ERKO livers raised several novel insights into the roles of ER in 634 
mouse liver. First, from a chromatin point of view, we observed that the enrichment of genes 635 
promoters in active marks globally paralleled their differential expression in ERKO as compared to 636 
ERWT livers. This correlation was slightly more important for up-regulated than down-regulated 637 
genes, suggesting that chromatin changes accompanying genes with higher transcriptional activity are 638 
more drastic than those observed for genes with reduced activity. Second, among the 129 genes 639 
differently expressed in the livers of ERKO vs. ERWT mice, only 10 were also regulated by E2 in 640 
ERWT. On the one hand, this observation could reflect the fact that the remaining 119 genes are 641 
indirectly regulated by ER, i.e. that one or more proteins or RNAs regulated by ER and/or E2 is 642 
required for the correct expression of these genes. Note that this faulty regulatory component could be 643 
expressed in the liver itself but since we used whole body ER knock-out (KO) mice it could also be 644 
expressed in other organs and indirectly influence the signalling cascades in the liver. This hypothesis 645 
is supported by the fact that these genes do not have any ER BSs in their vicinity. On the other hand, 646 
this observation also indicates that ER is not absolutely required for the basal expression of the 647 
majority of the E2-sensitive genes in the liver. This demonstrates in vivo that ER has to be considered 648 
as a regulator of transcription rather than a required factor for the transcription of these genes. Such a 649 
conclusion can also be drawn from our MeDIP-qPCR and H3K4me2/H3K27ac ChIP-seq data, which 650 
demonstrated that ER is not required per se for the establishment and/or maintenance of chromatin 651 
modifications at the majority of its binding sites. Moreover, we found that ER BSs with reduced 652 
chromatin functionality in ERKO are less frequently associated with the liver master regulator Hnf4α 653 
(76-80).  654 
These observations pointing at a secondary role of ER for the functionality of liver chromatin are 655 
also perfectly compatible with the notion that ER and other TFs act subsequent to the required 656 
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preliminary actions of pioneering factors such as FOXA proteins, or other partners such as GATA, 657 
C/EBP, etc (15,99,100) which determine the functionalization and accessibility of chromatin. 658 
However, contrasting with this pioneering view, we found that Foxa2 mobilization was affected in 659 
ERKO livers, even at ER-negative Foxa2 BSs identified in ERWT mice. Importantly, independent 660 
RT-qPCR or Western blot experiments did not consistently reproduce the 10% drop in Foxa2 661 
expression in ERKO livers detected by our microarray data. It is possible that the heterogeneity of the 662 
liver transcriptome and its dependence on the mouse diet may have hindered the detection of 663 
variations in Foxa2 expression. To get further information on a putative ER-mediated regulation of 664 
Foxa2, we hypothesized that if ER was controlling the expression of Foxa2 there might be genes 665 
regulated in the same way in ERKO and Foxa2KO mice. Comparison of our dataset with those 666 
available for a liver-specific double Foxa1/Foxa2 KO (22) revealed that 21 of the 721 Foxa-dependent 667 
mRNAs also had reduced expression in ERKO mice (data not shown). These genes exhibited no 668 
annotation towards a specific pathway or biological process. Although we cannot formerly exclude 669 
the possibility that Foxa2 expression may be influenced by the loss of ER expression, so far there is 670 
no clear evidence of a particular functional consequence of this putative direct relationship. 671 
Nevertheless, a 10% drop in Foxa2 expression may not be sufficient to explain a 50% loss in 672 
Foxa2 BSs. An in depth motif analysis associated with a comparison of Foxa2 BSs with the available 673 
cistromes of other TFs allowed us to provide an hypothetical model in which the binding of a network 674 
of other TFs on shared BSs may protect these sites from totally losing FoxA2 engagement and 675 
chromatin functionality. These factors are Hnf4α, Nkx3-1, Cebpα, Cebpβ and Rxrα and possibly 676 
Foxa1. Although we cannot ascertain the perfect specificity of our Foxa1 cistrome because of 677 
antibodies cross-reactivity with Foxa2, it may be interesting to note that 188 putative “ERKO-specific” 678 
Foxa1 sites were determined as lost Foxa2 BSs (data not shown). Interestingly, we also determined 679 
that regions that totally lost their central H3K4me2-enriched nucleosome were including DNA 680 
recognition motifs for Tead and Tcfap2 factors (Supplementary Fig. 14). AP2 is a pioneer factor, 681 
and may exert here a direct function in controlling chromatin opening. Tead factors, and in particular 682 
Tead 2 are involved in Foxa2/Hnf4α enhancer selection during hepatocyte differentiation (76). These 683 
two factors may therefore be integrated into the network of TFs that protect against chromatin 684 
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changes in ERKO livers. However, whether these factors direct the mobilization of chromatin 685 
modifiers that specifically prevent FoxA2 disengagement remains to be directly evaluated. Candidate 686 
modifiers could be proposed from our H3K4me2 ChIP-seq data showing a shift from a biphasic to a 687 
perfectly centered monophasic shape on some ER BSs and lost FoxA2 BSs. Two mechanisms could 688 
explain these observations: either the central nucleosome is preferentially modified by an H3K4 689 
methylase in ERKO livers (or the adjacent ones are not modified at all), or the absence of ER or 690 
FoxA2 directly or indirectly affects nucleosome positioning. In MCF-7 cells, ER genomic activity 691 
was shown to depend on the H3K methylases SMYD3, SETD1A, MLL1 or MLL2 (10,101-104), and 692 
even on its direct methylation by SMYD2 (105,106). However, mRNA encoding the orthologs of 693 
these proteins did not exhibit significant changes in ERKO relative to ERWT livers (not shown). The 694 
same was also true concerning the expression of histone chaperones involved in nucleosome 695 
positioning and dynamics, such as Spt16h and Ssrp1, components of FACT (107), or Spt6h and 696 
nucleolin (108).  697 
In conclusion, we have demonstrated here that the actions of ER and the acute administration of 698 
E2 in mouse liver in vivo have particular characteristics. Another important outcome of this study is 699 
the fact that ER is not absolutely required for the basal expression of the majority of the E2-sensitive 700 
genes in the liver and that it appears to be dispensable for the establishment and/or maintenance of 701 
chromatin modifications at the majority of its binding sites, where other TFs such as Hn4α may 702 
preserve functional competence. In contrast, ER was found required for the binding of the Foxa2 703 
factor. Taken together, together, our results indicate that the loss of ER expression in livers from 704 
ERKO mice affects the distribution of H3K4me2-enriched nucleosomes around both ER BSs and 705 
Foxa2 BSs. The underlying mechanisms still remain to be understood, although they are likely 706 
independent of the transcriptional regulation of chromatin actors. Importantly, besides its genomic 707 
influences, ER exerts membrane- and/or cytoplasmic-based actions on intracellular kinase 708 
transduction pathways (109). Hence, it would be interesting to test whether ER could regulate the 709 
activity of Foxa2 or H3K4 methylases at the post-translational level in liver using specific mouse 710 
models expressing ER forms devoid of either nuclear- (110,111) or membrane-based regulatory 711 
abilities (112,113).  712 
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FIGURE LEGENDS 1067 
Figure 1. Characterization of the E2-dependent genes in livers from ERWT and ERKO mice. A, 1068 
Heatmap illustrating the mean expression values determined for E2-sensitive genes (left side) in 1069 
placebo- (P) and 17β estradiol (E2)-treated ERWT animals or for genes whose expression was 1070 
different between placebo-treated ERWT and ERKO mice (right side). Each column corresponds to 1071 
data obtained for one animal. For the sake of clarity, expression values for each gene were normalized 1072 
by the mean and standard deviation. The percentages of up- and down-regulated genes are indicated 1073 
on the sides of each heatmap. B, Venn diagram depicting the overlap between genes regulated by E2 1074 
in ERWT livers and genes whose expression differed between ERWT and ERKO mice. 1075 
Figure 2. Characterization of the ER cistrome in mouse liver. A, ER ChIP-seq experiments were 1076 
performed on chromatin prepared from placebo- (P) or E2-treated ERWT and ERKO livers. We 1077 
systematically used different p-values at the peak-calling step to determine the ER cistrome under the 1078 
different conditions. This panel represents the number of identified ER BSs as a function of the p-1079 
values used. The color code used in panel A is the same for the next ones. B, Overlap of the different 1080 
ER cistromes obtained at diverse p-values. C, Venn diagram illustrating the common and specific ER 1081 
BSs using ER cistromes determined at a p-value of 10
-5
. D, Heatmap representation of the ChIP-seq 1082 
signal aligned to the center of ER BSs clustered depending on their overlap determined in panel C. E, 1083 
Mean ER ChIP-seq signals obtained in ERWT or ERKO mouse livers at the 150 center base pairs of 1084 
the BSs categories indicated beneath the graph. The upper histogram shows mean values ± SD 1085 
measured on the sites of interest whilst the bottom graph shows mean values ± SD of 10 trials carried 1086 
out on 10 different sets of a corresponding number of random sites. 1087 
Figure 3. Validation of ER BSs. (A and B) ER ChIP-qPCR experiments were performed on livers 1088 
from independent animals (numbers on the top of the panel) to validate ChIP-seq data. In Panel A, a 1089 
fraction of the pool of DNA that was subjected to high-throughput sequencing (HTS) was used as a 1090 
control. We used two panels of antibody: one directed against the C-terminal region of ER (left side 1091 
of panels A and B) and the other targeting the N-terminal domain of the protein (A and B, right side). 1092 
The mobilization of ER was evaluated on a series of genomic regions representing clusters of ER BSs 1093 
engaged by ER in the presence of E2 or not (#1) or BSs specific for ERKO (#2) or ERWT P (#3) 1094 
42 
conditions. The results of these experiments are illustrated as a heatmap of values normalized to those 1095 
of the promoter of the Rplp0 gene, which is an ER-negative region. We also used additional negative 1096 
and positive controls, located nearby the E2-sensitive Gdf15 gene: Gdf15.2 and Gdf15.3, respectively. 1097 
In panel B, the results of the experiments were hierarchically clustered to improve the clarity of the 1098 
heatmap. The distance metric expressed as Pearson correlation is indicated on the right side of the 1099 
panel. N.D stands for not determined. 1100 
Figure 4. Specific features of the ER cistrome in mouse liver. A, Distribution of ER BSs determined 1101 
in E2- or placebo-treated ERWT mouse liver towards annotated gene promoters and TTSs, exons and 1102 
introns, and intergenic (distal) regions. B, Number of ER BSs located within a 1kb or 3kb window 1103 
around the TSS of annotated genes in ERWT (P+E2) mouse liver when compared to ER binding data 1104 
obtained in human breast cancer MCF-7 cells. Calculations were also made using an equivalent 1105 
number of random regions with similar characteristics than the test ER cistrome determined in ERWT 1106 
livers. C, Bar chart summarizing the distribution of distances separating E2-regulated genes in breast 1107 
cancer cell lines or in ERWT mice liver or ER-dependent genes from their closest ER BS. Results are 1108 
expressed as the percentage of the total population of genes considered. D, Fold-changes in gene 1109 
expression by E2 in MCF-7 and ERWT mouse liver and in ERKO vs. ERWT liver are expressed as a 1110 
function of their proximity to an ER BS. Distribution of values are depicted within the left part of the 1111 
panel, while means ± SD are plotted on the right side of the panel. 1112 
Figure 5. Coordinated changes in H3K4me2 and H3K27ac levels at promoters of ER-dependent 1113 
genes. A, Alignment of H3K4me2 and H3K27ac ChIP-seq signals generated from chromatin prepared 1114 
from E2-treated livers of ERWT (red line) or ERKO (blue line) mice on a -5kbp/+5kbp window 1115 
around the center of the ER BSs. B and C, Mean H3K4me2 and H3K27ac ChIP-seq signals at a -1116 
500/+500 bp window around the center of ERBSs (B) or within a 4 kb window centered around the 1117 
TSS of genes with lower or higher expression in ERKO livers (down-or up-regulated, respectively). D, 1118 
The fold-change of mean H3K27 values calculated for each of the promoters of down-or up-regulated 1119 
genes in ERKO livers are plotted against variations of mean H3K4me2 signals. Values shown are 1120 
expressed as the log2 of the fold-changes. 1121 
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Figure 6. Affected profile of H3K4me2 enrichment of a fraction of ERBSs in ERKO livers. A, 1122 
Heatmap representation of a k-mean clusterization of H3K4me2 and H3K27ac ChIP-seq signals 1123 
obtained in ERWT and ERKO mice livers on ERWT ER BSs. The distribution of clustered ER BSs 1124 
towards annotated genes’ transcriptional start and termination sites (TSS and TTS, respectively), 1125 
intragenic and intergenic (Distal) regions is indicated on the right side of each clusters, as well as the 1126 
numbers of genomic sites within each cluster. B, Alignments of H3K4me2 and H3K27ac ChIP-seq 1127 
mean signals within a -5kbp/+5kbp window centered on ER BSs of each clusters as defined from the 1128 
k-mean analysis. Signals obtained in E2-treated livers of ERWT or ERKO mice are illustrated as a red 1129 
or blue line, respectively. Insets represent magnified views of the center of the graphs and illustrate 1130 
the observed shift from biphasic to monophasic curves of enrichment in H3K4me2. 1131 
Figure 7. Chromatin status of ER BSs in ERWT and ERKO mouse livers. A, Independent anti- 1132 
H3K4me1, H3K4me2 and H3K27ac ChIP-qPCR experiments were performed to validate ChIP-seq 1133 
data. The presence of these marks on ER BSs from series #1 and #3, as defined in Fig. 3, is depicted 1134 
within the illustrated heatmaps. Numbers on the top refer to the animals from which the chromatin 1135 
preparations originated. Experiments were done twice per individual. Mean enrichment values 1136 
calculated per individual are shown as normalized to a control negative ChIP experiment using the 1137 
same chromatin samples. B, Heatmap illustrating the mean enrichment of indicated ER BSs in 5-mC 1138 
and 5-hmC as tested by MeDIP- and hMeDIP-qPCR experiments, respectively. The values included 1139 
within these graphs were obtained from three independent experiments performed on two different 1140 
DNA samples originating from two different ERWT or ERKO animals. Data were normalized to 1141 
values obtained using an internal negative control devoid of CpGs. Significant reduced (green) or 1142 
gained (red) enrichment in histone marks or DNA modifications ERKO livers are indicated in the 1143 
heatmaps on the right side of each panels. Calculated p-values from Mann-Whitney t-tests are 1144 
indicated within the heatmap as follows: *< 0.05; **<0.01. 1145 
Figure 8. Overlap of ER and Hnf4α cistromes. A, Overlap of the ER BSs determined in E2-treated 1146 
ERWT livers with those of Hnf4α obtained at diverse p-values. B, Heatmap representation of ER and 1147 
Hnf4α ChIP-seq signals within a -5kbp/+5kbp window centered on ER BSs. Regions are sorted by 1148 
their rank in ER ChIP-seq signal. C, Heatmap representing the overlap between the clusters of ER 1149 
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BSs as determined in Fig. 6 with Hnf4α BSs determined at a p-value of 10
-5
. The numbers indicated 1150 
represent the calculated overlaps.  1151 
Figure 9. The Foxa2 cistrome is partially ER-dependent. A, Foxa2 ChIP-seq experiments were 1152 
performed on chromatin prepared from E2-treated ERWT and ERKO livers. As carried out previously, 1153 
we systematically used different thresholds to determine the number of Foxa2 BSs in each of the 1154 
experimental conditions (orange and grey lines for ERWT and ERKO animals respectively). The 1155 
number of ER BSs in ERWT (red curve) is given as reference. The color code used in panel A is the 1156 
same for the next ones. B, Overlap of the different Foxa2 cistromes at diverse p-values with ER BSs 1157 
or Foxa2 BSs determined in E2-treated ERWT livers (left and middle graphs), or Foxa2 BSs in E2-1158 
treated ERKO livers (right). C, Venn diagram illustrating the overlap of ER BSs with Foxa2 BSs in 1159 
ERWT or ERKO mice at the chosen p-value of 10
-4
. D, Heatmap of Foxa2 normalized ChIP-seq 1160 
signals obtained from ERWT or ERKO chromatin on conserved, lost or gained Foxa2 BSs. E, Mean 1161 
Foxa2 ChIP-seq signals obtained in ERWT or ERKO mouse livers (orange or grey bars, respectively) 1162 
at the 150 center base pairs of Foxa2 BSs. The upper histogram shows mean values ± SD measured 1163 
for conserved, gained or lost sites. Calculations were also carried out for 10 different sets of a 1164 
corresponding number of random sites. Means ± SD of these 10 random trials are illustrated within 1165 
the bottom histogram. F, Anti-Foxa2 ChIP-qPCR experiments were performed on four liver 1166 
chromatin samples originating from independent E2-treated ERWT or ERKO mice. A fraction of the 1167 
pooled DNA sample that was subjected to HTS was also evaluated in parallel. The upper heatmap 1168 
shows the values obtained on indicated tested genomic regions normalized to those obtained from a 1169 
non-specific control (promoter of the Rplp0 gene) and to the control ChIP sample. Significant reduced 1170 
(green) or gained (red) mobilization of Foxa2 in ERKO livers is indicated in the lower heatmap. 1171 
Calculated p-values from Mann-Whitney t-tests are indicated as follows: *< 0.05; **<0.01. 1172 
Figure 10. Chromatin status of Foxa2 BSs in ERWT and ERKO mouse livers. A and B, Alignment of 1173 
mean H3K4me2 (left side of the panel) or H3K27ac signals on categorized Foxa2 BSs. Insets 1174 
represent magnified views of the center of the graphs and illustrate the observed shift from biphasic to 1175 
monophasic curves of enrichment in H3K4me2. C, Heatmap representation of results obtained in 1176 
independent anti H3K4me1, H3K4me2 and H3K27ac ChIP-qPCR experiments. The presence of these 1177 
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marks was followed in livers from ERWT and ERKO animals (numbers on the right refer to 1178 
individuals) at the indicated conserved or lost Foxa2 BSs. Experiments were done twice per individual. 1179 
Mean fold enrichment values shown are expressed as relative to a control negative ChIP experiment 1180 
using the same chromatin samples. D, Summary of MeDIP- and hMeDIP-qPCR assays, illustrated as 1181 
in panel B. The values included within these graphs were obtained in three independent experiments 1182 
performed on two different DNA samples originating from two different ERWT or ERKO animals. 1183 
Significant reduced (green) or gained (red) enrichment in histone marks or DNA modifications in 1184 
ERKO livers are indicated in the lower heatmaps. Calculated p-values from Mann-Whitney t-tests are 1185 
indicated as follows: *< 0.05; **<0.01. 1186 
Figure 11. Multiple TFs may protect Foxa2 BSs from loss-of function in ERKO livers. A, Wordle 1187 
graphics (http://www.wordle.net/website) of enriched motifs for transcription factors binding within 1188 
lost Foxa2 BSs; as determined by the SeqPos algorithm (http://cistrome.org/ap/). B, Overlap of 1189 
categorized Foxa2 BSs with the cistromes of different transcription factors, all determined in mouse 1190 
liver except Nkx3-1 BSs which were identified in mouse prostate. 1191 
Table 1. E2- and ER-dependent liver transcriptomes associated functions. 
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lipid metabolic process 0.063 
regulation of fibroblast growth factor receptor signaling pathway 0.063 
fibroblast growth factor receptor signaling pathway 0.063 
negative regulation of cellular response to growth factor stimulus 0.063 
negative regulation of fibroblast growth factor receptor signaling pathway 0.063 
alcohol metabolic process 0.063 
intracellular signal transduction 0.063 
enzyme linked receptor protein signaling pathway 0.063 
small molecule metabolic process 0.078 
organic substance metabolic process 0.078 
cellular response to fibroblast growth factor stimulus 0.078 
polyol metabolic process 0.078 
response to fibroblast growth factor stimulus 0.078 
E
R
-d
e
p
e
n
d
e
n
t 
(-
E
2
) 
negative regulation of biological process 0.0008 
growth 0.0008 
oxidation-reduction process 0.0008 
negative regulation of cellular process 0.0014 
mammary gland development 0.0014 
regulation of growth 0.0020 
mammary gland alveolus development 0.0052 
mammary gland lobule development 0.0052 
developmental process 0.0052 
positive regulation of cell differentiation 0.0052 
metabolic process 0.0052 
multicellular organismal development 0.0081 
reactive oxygen species metabolic process 0.0081 
negative regulation of growth 0.0081 
lipid metabolic process 0.0090 
positive regulation of reactive oxygen species metabolic process 0.0090 
single-organism metabolic process 0.0090 
positive regulation of developmental process 0.0090 
positive regulation of glucose import 0.0090 
organ development 0.0091 
regulation of body fluid levels 0.0091 
system development 0.0091 
anatomical structure development 0.0091 
regulation of glucose metabolic process 0.0091 
gastrulation with mouth forming second 0.0091 
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E
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e
 Adipogenesis  (Wiki) 0.0021 
Metabolic pathways (Kegg) 0.0024 
Cytokine-cytokine receptor interaction (Kegg) 0.0036 
E
R
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e
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e
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e
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t 
(-
E
2
) 
Adipogenesis (Wiki) 6.53e-06 
IL-3 Signaling (Wiki) 2.97e-05 
Leptin Insulin Overlap (Wiki) 5.94e-05 
ErbB signaling (Wiki) 0.0008 
PPAR signaling (Wiki) 0.0022 
IL-6 signaling (Wiki) 0.0032 
Amino Acid metabolism (Wiki) 0.0032 
Androgen Receptor Signaling (Wiki) 0.0035 
Metabolic pathways (Kegg) 2.43e-08 
Adipocytokine signaling (Kegg) 0.0001 
Glycine, serine and threonine metabolism (Kegg) 0.0003 
Fatty acid metabolism (Kegg) 0.0005 
Type II diabetes mellitus (Kegg) 0.0005 
Jak-STAT signaling pathway (Kegg) 0.0009 
Bile secretion (Kegg) 0.0011 
Retinol metabolism (Kegg) 0.0012 
PPAR signaling pathway (Kegg) 0.0012 
Arachidonic acid metabolism (Kegg) 0.0014 
Hepatitis C (Kegg) 0.0042 
Insulin signaling pathway (Kegg) 0.0042 
Functional annotations are shown for GO Biological processes and for a compilation of Wiki and Kegg pathways. Adjusted Bonferroni p-
values are indicated (adjP). 
Table 2. Enriched DNA Motifs in identified ERBSs. 
ERWT E2 ERWT P ERKO 
CentDist SeqPos CentDist SeqPos CentDist SeqPos 
Motif 
Family 
 
Score 
 
Factor 
Z-
Score 
Motif 
Family 
 
Score 
 
Factor 
Z-
Score 
Motif 
Family 
 
Score 
 
Factor 
Z-
Score 
ERE 63.3457 ESR1 -54.177 ERE 19.8389 ESR1  -16.769 
No Motif 
identified 
 SREBF1  -2.823 
AR 27.5415 ESR2 -48.709 AR 9.2016 ESR2  -15.407  E2F6  -2.55 
CEBP 19.9196 NR1H4 -41.196 SP1 7.07288 PPARG  -10.533    
CREB 17.3222 NR2F1 -38.985 CREB 6.725 Nr1d2  -9.025    
NF1 14.969 Nr1d2 -35.506 AP2 6.55955 PPARG::RXRA  -7.921    
FOX 14.6542 Rxra -34.347 NRF 6.27122 Rxra  -7.705    
LRH1 14.6223 PPARG -30.851 E2F 6.00375 NR1H4  -7.519    
SP1 13.5031 PPARA -30.684 MINI 5.66217 NR2F1  -7.021    
PAX 13.3069 Esrrb -28.943 HIC1 5.1859 RORB  -6.933    
E2F 13.2217 Nr1d1 -27.169 CEBP 5.1783 Nr1d1  -6.739    
FXR 12.0634 Nr2f2 -25.821 ETS 5.10736 PPARA  -6.595    
AP4 12.014 RORB -25.117 EGR 5.08289 AR  -4.809    
AP2 11.8928 RARA -25.044 SP3 5.00439 Zscan10  -4.476    
HIC1 11.8863 PPARG::RXRA -24.754 ZF5 4.87866 Zfp161  -4.295    
HEN 11.097 ESRRA -23.913 P53 4.82231 EGR3  -4.147    
AP1 10.8325 Hnf4a -23.697 LMAF 4.81312 HMGN1  -4.1    
ARP1 10.6548 NR0B1 -22.347 NF1 4.71645 ZSCAN4  -4.014    
ZF5 10.6078 RXRB -21.033 EBOX 4.64247 NR3C1  -3.894    
MEF3 10.5625 NR4A1 -20.62 GGG 4.44056 Rarg  -3.742    
MINI 10.5463 NR2C2 -20.308 FOX 4.33386 NR0B1  -3.544    
EBOX 10.5284 Rxrg -20.177 CP2 4.1856 GMEB2  -3.438    
MIF1 10.3304 RORA -20.112 SMAD 4.04632 NR2C2  -3.433    
GGG 10.2881 Rarg -19.838 EBF 3.95207 EGR4  -3.42    
SMAD 10.1529 Nr5a2 -19.729 DEAF1 3.93445 Esrrb  -3.401    
LEF 9.80931 Cebpb -18.033 PAX 3.88007 E2F3  -3.353    
HNF1 9.73785 Cebpa -17.783 CAAT 3.86651 MTF1  -3.329    
HNF6 9.55107 CEBPE -17.524 HEN 3.86643 NR3C2  -3.179    
ATCGAT 9.48478 SF1 -16.74 STAT 3.81298 RXRB  -3.161    
BACH 9.09395 AR -16.689 AP4 3.76367 PAX2  -3.14    
CACCC 9.07574 NR6A1 -16.346 DBP 3.75713 Mafb  -3.116    
DBP 8.80169 CEBPD -16.334 SRF 3.58963 E2F2  -3.069    
NRF 8.75417 THRB -15.294 KAISO 3.5676 TP63  -2.723    
VMAF 8.74793 CEBPG -15.105 CACCC 3.55511 PGR  -2.622    
P53 8.57691 NR3C1 -14.897 MEIS1 3.54119 NANOG  -2.603    
LMAF 8.54137 VDR -14.558 IK 3.32866 VDR  -2.529    
CAAT 8.30663 NR3C2 -14.523 LRH1 3.1906 Egr2  -2.509    
CP2 8.17824 NR2F6 -14.179 WT1 3.17195      
  NR4A2 -14.073 ZNF219 3.14613      
  ESRRG -13.415 RFX 3.0712       
  ATF2 -13.373 STAF 2.9954      
  ATF2::JUN -13.185        
  ATF6 -12.984        
  THRA -12.737        
  Jdp2 -12.54        
  THRB -12.515        
  CREB3 -11.811        
  RARB -11.735        
  NFIX -11.73        
  NFIB -11.623        
  ATF4 -10.996        
  NR2E3 -10.893        
  Creb5 -10.694        
  PAX2 -10.551        
  ATF1 -10.415        
  NFIC -10.269        
  BATF3 -10.214        
  ATF7 -10.207        
  Foxa2 -9.851        
  PGR -9.837        
  FOXA1 -9.831         
  Creb3l2 -9.414         
  NR1I2 -9.322         
  NFIL3 -9.241         
  Pax3 -9.197         
 
 
Motif analysis was performed using CentDist (http://biogpu.ddns.comp.nus.edu.sg/~chipseq/webseqtools2) and SePos 
(http://cistrome.org/ap/) algorithms. Sequences were declared enriched by when p-value<0.05  and Z-score>2.5. Only the 
65 best sequences characterized by SeqPos are shown for ERBSs identified in E2-treated ERWT animals. Full analyses are 
depicted in the Supplemental File 3.  
Table 3. Functional annotations of genes proximal to ERBSs from ERWT livers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functional annotations were determined by GREAT [http://bejerano.stanford.edu/great/public/html/index.php (51)] using basic 
parameters (basal criteria for associating genomic regions with genes). 
 
 
 Term p-value 
M
G
I 
E
x
p
re
ss
io
n
 TS23_liver; lobe 4.22e-40 
TS26_liver 6.67e-32 
TS26_liver and biliary system 1.03e-31 
TS24_liver 1.56e-27 
TS24_liver and biliary system 2.66e-24 
TS15_septum transversum; hepatic component 1.11e-15 
TS23_adrenal gland; medulla 3.13e-13 
G
O
 B
io
lo
g
ic
a
l 
P
ro
ce
ss
 organic acid metabolic process 3.69e-49 
carboxylic acid metabolic process 2.74e-48 
cellular ketone metabolic process 6.43e-48 
lipid metabolic process 7.95e-48 
cellular response to hormone stimulus 1.87e-43 
cellular response to peptide hormone stimulus 1.25e-40 
monocarboxylic acid metabolic process 7.54e-38 
cellular response to insulin stimulus 4.52e-37 
response to peptide hormone stimulus 7.26e-36 
response to insulin stimulus 2.78e-35 
G
O
 M
o
le
cu
la
r 
F
u
n
ct
io
n
 lyase activity 7.09e-15 
monocarboxylic acid binding 4.91e-14 
heme binding 2.99e-13 
apolipoprotein binding 6.24e-13 
transferring acyl groups 5.44e-11 
carboxylic acid binding 1.85e-12 
steroid binding 5.63e-12 
vitamin binding 2.74e-11 
steroid hydroxylase activity 1.69e-10 
ligand-regulated transcription factor activity 1.02e-09 
M
o
u
se
 P
h
e
n
o
ty
p
e
 
abnormal lipid homeostasis 9.28e-75 
abnormal lipid level 1.01e-71 
abnormal circulating lipid level 8.51e-70 
abnormal liver physiology 8.41e-63 
abnormal hepatobiliary system physiology 8.27e-62 
abnormal triglyceride level 4.24e-61 
decreased cholesterol level 1.01e-52 
abnormal circulating cholesterol level 5.19e-52 
abnormal cholesterol level 1.09e-51 
abnormal cholesterol homeostasis 4.65e-50 
Table 4. Enriched DNA Motifs in categorized FoxA2 BSs. 
Conserved  Gained  Lost  
Factor Z-Score Factor Z-Score Factor Z-Score 
Foxa2 -91.617 Foxa2 -23.414 Foxa2 -59.79 
FOXA1 -90.958 FOXA1 -23.058 FOXA1 -59.536 
FOXI1 -81.908 FOXI1 -22.795 FOXI1 -56.216 
Foxg1 -80.449 FOXB1 -21.524 Foxg1 -54.751 
FOXB1 -78.905 FOXP1 -21.512 FOXP1 -52.788 
FOXP1 -78.788 Foxg1 -21.297 Nkx3-1 -52.633 
FOXD2 -75.482 Foxk1 -20.161 FOXB1 -50.984 
FOXD3 -74.081 FOXL1 -19.777 FOXL1 -50.971 
FOXL1 -73.89 FOXD2 -19.095 FOXD2 -48.341 
Nkx3-1 -72.907 Nkx3-1 -18.785 FOXD3 -47.994 
Foxk1 -72.123 FOXD3 -18.614 Foxk1 -47.988 
FOXD1 -70.968 FOXD1 -17.878 FOXD1 -46.354 
FOXC2 -67.3 FOXP3 -17.007 FOXP3 -44.639 
FOXC1 -66.927 FOXO3 -16.517 FOXO3 -43.621 
FOXO3 -66.241 FOXC2 -15.411 FOXC2 -39.98 
FOXP3 -64.662 FOXC1 -14.102 FOXC1 -35.118 
FOXF2 -51.748 FOXF2 -13.535 FOXF2 -34.484 
Foxj1 -51.576 CEBPD -12.481 Foxj1 -33.619 
FOXJ3 -45.412 Cebpb -12.292 Foxf1a -29.292 
Foxf1a -40.616 CEBPE -12.152 FOXJ3 -26.531 
FOXH1 -32.447 Cebpa -11.812 FOXH1 -22.446 
CEBPE -27.482 Foxj1 -11.6 Hnf4a -15.71 
Cebpb -27.19 CEBPG -11.278 Cebpb -15.134 
CEBPA -26.856 FOXJ3 -9.067 CEBPA -14.552 
CEBPD -26.765 Foxf1a -8.978 CEBPE -14.418 
HNF4A -26.219 Hnf4a -8.801 CEBPD -14.338 
Foxq1 -24.216 FOXH1 -8.068 CEBPG -13.844 
CEBPG -22.81 RXRB -7.845 NR2C2 -13.376 
FOXG1 -19.912 RXRA -7.44 Rxrb -12.575 
NR2C2 -19.459 NR2F6 -7.128 NR2F1 -11.973 
FOXJ2 -19.292 PPARA -7.113 Ppara -11.972 
RXRB -19.023 HLF -7.05 NR2F6 -11.776 
NR2F6 -18.985 NFIL3 -6.95 NR1H4 -11.079 
RARA -17.842 RARA -6.798 Nr1d2 -10.656 
NR2F1 -17.813 NR2C2 -6.428 RARA -10.297 
Nr2f2 -16.99 DBP -6.041 Foxq1 -10.091 
NR1H4 -16.511 Nr1d2 -5.836 FOXJ2 -9.851 
NR2E3 -16.142 ATF4 -5.821 Rxra -9.762 
NR4A1 -16.003 NR1H4 -5.659 NFIX -9.739 
Nr1d2 -15.912 NR2F1 -5.438 Nr2f2 -9.385 
Ppara -15.867 ZSCAN4 -5.432 ZSCAN4 -9.131 
SRY -15.493 Pparg -4.988 NFIC -8.927 
ZNF435 -15.351 Nr2f2 -4.944 FOXO6 -8.69 
NFIL3 -15.241 Creb5 -4.864 Zscan10 -8.445 
ESRRA -15.067 NFIB -4.757 NR4A1 -8.393 
ATF4 -14.596 ATF7 -4.756 ESRRA -8.372 
FOXO4 -14.388 TEF -4.756 NFIB -8.199 
FOXO6 -13.684 NR2E1 -4.534 HEY1 -8.186 
NFIC -13.639 Foxq1 -4.379 NR2E3 -8.143 
Rxra -13.167 NFIX -4.329 Esrrb -8.116 
      
 
Motif analysis was performed using SeqPos algorithm (http://cistrome.org/ap/). Sequences were declared enriched by 
when p-value<0.05  and Z-score>2.5. Only the best 50 sequences characterized are shown. Full analyses are depicted in the 
Supplemental File 3. 
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